The date is approaching fast and we’re making preparations. Don’t miss out!
DaysDays
HrsHours
MinsMinutes
SecsSeconds
Please review the information available throughout this page. If you are interested in learning more and participating in the clinical trial, you can request a meeting with a member of the study team.
In September 2022 OvaryIt was Awarded a Phase 1 feasibility study. The results were published in the Journal of the American Medical Informatics Association Open: Phase 1 Publication
Shortly after, in March 2023 OvaryIt was invited to participate in the NIH “incubator” program, I-Corps. There we completed nearly 150 interviews with pharmacists, pharmacy owners, and industry leaders to ensure feasibility and product market fit.
In August 2024, OvaryIt was awarded a Phase 2 NIH grant to commercialize a platform empowering pharmacists to prescribe contraception. This clinical trial is an integral part of the ongoing Phase 2 initiative.
This study is a 12-week pilot program conducted at select pharmacies across the United States. Participating pharmacists will use the PRISM software platform to deliver contraceptive services directly in a community pharmacy setting. The platform is intended to streamline workflows and provide clinical decision support to facilitate pharmacist-led care. Your participation will not only give patients in your community convenient access to contraceptive services but will also generate valuable real-world data on the feasibility of implementing these services using the PRISM platform. Furthermore, the insights gained from this study may help fill a critical gap in the literature regarding pharmacist-led contraceptive care, potentially informing strategies to broaden adoption nationwide, which could enhance patient access and support future efforts to expand pharmacists’ scope of practice.
There are many benefits to join the study:
Please reach us at support@ovaryit.com if you cannot find an answer to your question.
To assess the PRISM platform’s impact on pharmacist-led contraceptive services implementation, efficiency, patient outcomes, and usability in real-world pharmacy settings.
Patient encounters will occur in the pharmacy and documented using the PRISM platform, with pharmacists ensuring that the care is patient-centered and compliant with the USMEC guidelines.
Yes, participation is voluntary, and you may withdraw at any time without penalty.
Please review the information available throughout this page. If you are interested in learning more and participating in the clinical trial, you can request a meeting with a member of the study team.
Copyright © 2025 OPP - All Rights Reserved.
Powered by OvaryIt